免疫调节剂联合治疗对炎症性肠病患者抗肿瘤坏死因子拮抗剂谷浓度及抗药抗体的影响:一项Meta分析
该Meta分析纳入35项研究、6790例炎症性肠病患者,评估免疫调节剂联合抗TNF治疗对ADA形成及抗TNF谷浓度的影响。联合治疗组ADA形成风险比单药治疗组降低(汇总风险比0.49,95%CI 0.41-0.59,P<.001),但抗TNF谷浓度无显著差异(SMD 0.11,95%CI 0.19-0.41,P=.47)。
要点
- 联合免疫调节剂与抗TNF单药相比,ADA形成风险比为0.49(95%CI 0.41-0.59,P<.001)。
- 联合与否在抗TNF谷浓度上无显著差异(SMD 0.11,95%CI 0.19-0.41,P=.47)。
- 不同抗TNF药物间ADA形成无差异(交互作用P=.50),保护效应不受免疫调节剂种类或ADA检测方法影响。
核心结论
- 在已发表研究的Meta分析中,免疫调节剂联合治疗与炎症性肠病患者抗TNF拮抗剂抗体形成风险降低相关。
研究设计与样本
- 系统检索文献数据库,纳入报告抗TNF治疗患者ADA患病率的研究,汇总符合纳入标准研究的原始数据以确定效应估计。
- 共分析35项符合纳入标准的研究,结果报告自6790例炎症性肠病患者。
主要发现
- 接受免疫调节剂联合治疗患者与接受抗TNF单药治疗患者相比,ADA形成的汇总风险比为0.49(95%CI 0.41-0.59;P<.001)。
- 联合使用免疫调节剂与未联合使用相比,抗TNF药物谷浓度无显著差异(标准化均数差0.11;95%CI 0.19-0.41;P=.47)。
- 按不同TNF拮抗剂治疗患者进行的亚组分析显示ADA形成无差异(交互作用P=.50)。
- 免疫调节剂的保护效应不因患者所用药物类型(甲氨蝶呤 vs 硫嘌呤类)或ADA检测方法而异。
- 仅在溃疡性结肠炎患者的研究中观察到异质性(I²=76%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 仅在溃疡性结肠炎患者的研究中观察到异质性(I²=76%)。
- 漏斗图和Egger检验分析提示研究存在发表偏倚(P=.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is not clear whether combination therapy with immunomodulators affects the immunogenicity of tumor necrosis factor (TNF) antagonists in patients with inflammatory bowel disease. We performed a meta-analysis to quantify the effects of combined immunomodulator therapy on the presence of antibodies against TNF antagonists (antidrug antibodies [ADAs]) and trough levels of anti-TNF agents. METHODS: We systematically searched publication databases for studies that reported prevalence of ADAs in patients who received anti-TNF agents. Raw data from studies that met the inclusion criteria were pooled to determine effect estimates. We performed subgroup and metaregression analyses to determine the level of heterogeneity among study outcomes. RESULTS: We analyzed findings from 35 studies that met inclusion criteria (results reported from 6790 patients with inflammatory bowel disease). The pooled risk ratio for formation of ADAs in patients receiving combined therapy with immunomodulators, versus that of patients receiving anti-TNF monotherapy, was 0.49 (95% confidence interval, 0.41-0.59; P < .001). However, the pooled analysis did not demonstrate a significant difference in trough levels of anti-TNF agents between patients with versus without concurrent use of immunomodulators (standardized mean difference, 0.11; 95% confidence interval, 0.19-0.41; P = .47). Subgroup analyses of patients treated with different TNF antagonists revealed no difference in the formation of ADAs (P = .50 for interaction); the protective effect of immunomodulators did not differ with type of drug patients were given (methotrexate vs thiopurines), or assay for ADA. We observed heterogeneity only among studies of patients with ulcerative colitis (I2 = 76%). Funnel plot and Egger test analyses indicated publication bias in the studies (P = .001). CONCLUSIONS: In a meta-analysis of published studies, we associated combined treatment with immunomodulators with reduced risk of formation of antibodies against TNF antagonists in patients with inflammatory bowel disease.
引用
- Qiu Y, Mao R, Chen BL, et al. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Clin Gastroenterol Hepatol. 2017. PMID: 28232073. doi:10.1016/j.cgh.2017.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。